Explore our science.
You are not alone in the battle against cancer.
Learn about the next generation in precision oncology.
Learn more about our clinical trials and how you can contribute to the future of cancer care.
We are a next generation radiopharmaceutical company, taking cancer head on.
Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.
We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.
With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.
Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release. PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial.